Scarica l'app Stockscreener
35.63
0.11%
0.04
Dopo l'orario di chiusura:
35.50
-0.13
-0.36%
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Ionis gets FDA approval for Tryngolza - MSN
Ionis notches Arrowhead win; Tryngolza cleared for FCS - BioWorld Online
Ionis To Get Head Start On Arrowhead With Tryngzola Launch - Citeline News & Insights
Ionis gets a milestone approval; Another top FDA official to step down - BioPharma Dive
FDA approves Ionis’ TRYNGOLZA for FCS treatment - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Outperform" Rating from William Blair - MarketBeat
FDA approves Ionis’ Tryngolza - The Pharma Letter
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Yahoo Finance UK
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome - BioSpace
Ionis stock rises following FDA approval of TRYNGOLZA By Investing.com - Investing.com Canada
Ionis stock rises following FDA approval of TRYNGOLZA - Investing.com
FDA Approves Ionis Pharmaceuticals' (IONS) First Fully Owned Dru - GuruFocus.com
Olezarsen Earns First-Ever FDA Approval for Familial Chylomicronemia Syndrome - MD Magazine
Ionis Secures Historic FDA Approval for First-Ever FCS Treatment, TRYNGOLZA Shows 57% Triglyceride Reduction - StockTitan
US FDA approves Ionis Pharma's genetic disorder drug - Reuters
Ionis wins FDA approval for a rare disease therapy that lowers triglycerides - STAT
Ionis to hold third quarter 2024 financial results webcast - The Eastern Progress Online
RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR
Geode Capital Management LLC Increases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Update - MarketBeat
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Ionis Pharmaceuticals, Inc. announced that it expects to receive $624.972654 million in funding from Biogen Inc. - Marketscreener.com
Trend Tracker for (IONS) - Stock Traders Daily
Y Intercept Hong Kong Ltd Acquires Shares of 20,141 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Stifel Financial Corp - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval - Citeline
XTX Topco Ltd Takes $673,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% - MSN
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks
Ionis to present at upcoming investor conferences - Longview News-Journal
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year By Investing.com - Investing.com Nigeria
Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease - The Eastern Progress Online
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Groupama Asset Managment - MarketBeat
Ionis announces proposed public offering of common stock - The Eastern Progress Online
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More - BioSpace
Narrow-Moat Ionis Is Expanding Its Neurology and Cardiology Portfolio to Strengthen Its Moat - Morningstar
Ionis announces pricing of $500.3 million public offering - The Eastern Progress Online
Ionis Pharmaceuticals : announces appointment of Brett P. Monia Ph.D. to its board of directors - Marketscreener.com
Ionis Pharmaceuticals : to Provide Corporate Update at 2019 Annual Meeting of Stockholders - Marketscreener.com
Ionis Pharmaceuticals : Provides Corporate Update at 2018 Annual Meeting of Stockholders - Marketscreener.com
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Theratechnologies expands rare disease portfolio with Ionis partnership - MSN
Company plans to seek Canada OK of HAE treatment donidalorsen - Angioedema News Today
Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance
Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing
Theratechnologies Expands Portfolio with Ionis Deal - TipRanks
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada - The Manila Times
Theratechnologies Announces Exclusive Licensing Agreement - GlobeNewswire
Theratechnologies Secures Exclusive Rights to Two Breakthrough Rare Disease Drugs in $22.75M Deal - StockTitan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Raised by Jacobs Levy Equity Management Inc. - MarketBeat
51,300 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Erste Asset Management GmbH - MarketBeat
Nine PDUFA dates on FDA’s December calendar - BioCentury
The Manufacturers Life Insurance Company Has $12.38 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Baker BROS. Advisors LP Buys Shares of 223,470 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Lowered by Bellevue Group AG - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):